FFAR2 and graft versus host disease: SCFAs can improve GVHD by inhibiting HDAC activity and binding to GPR43, which differs from other known mechanisms of these signal transduction inhibitors, and suggests that SCFAs may provide a new treatment option for GVHD patients.